Krishnan Suma sold $96K of KRYS
Krishnan Suma (President, R&D) sold 320 shares of Krystal Biotech, Inc. (KRYS) at $300.75 on 2026-06-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure updates the insider activity record but does not, by itself, indicate a new fundamental event (no earnings, trial, deal, or regulatory action mentioned).
Market read
Primarily a sentiment/positioning datapoint; likely low incremental trading signal due to 10b5-1 pre-arrangement.
What to watch
Traders may over-weight insider selling; the key differentiator is whether the plan is pre-arranged (it is) and whether there are concurrent buys/sales in the same window (not provided here).
Background
SEC Form 4 reports an insider’s transaction in the issuer’s own shares; this one is an open-market sale by a senior officer/10% owner with a pre-arranged 10b5-1 plan.
Ticker impact
Krystal Biotech insider Krishnan Suma (President, R&D; 10% owner) sold 320 shares in an open-market transaction under a 10b5-1 plan.
Limited immediate price impact; any reaction is likely sentiment-driven and short-lived.
The filing is a routine insider transaction with explicit 10b5-1 pre-arrangement, reducing the probability it reflects new negative information.
Market effects
Minimal; this is company-specific insider disclosure with no stated operational/regulatory catalyst.
None expected beyond routine microstructure/sentiment effects in US biotech.
None expected.
Counterpoint
Because the sale is under a pre-arranged 10b5-1 plan, it may be mechanically scheduled and not predictive of fundamentals.
Key entities
- issuerKrystal Biotech, Inc.
Subject of the Form 4 insider transaction; insider sale disclosed for KRYS shares.
- insiderKrishnan Suma
President, R&D; officer/director/10% owner who sold 320 shares on 2026-06-04 under a 10b5-1 plan.
